SHPMF: AI 评分 45/100 — AI 分析 (4月 2026)

Shanghai Pharmaceuticals Holding Co., Ltd. is a leading Chinese pharmaceutical company involved in the research, development, manufacturing, distribution, and retail of pharmaceutical products. The company operates across multiple segments, including production, distribution, and retail, with a focus on various therapeutic areas.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the Chinese pharmaceutical market, with a diversified portfolio spanning drug manufacturing, distribution, and retail. The company's extensive network of retail pharmacies and focus on key therapeutic areas position it competitively within China's growing healthcare sector, supported by a beta of 0.33.

SHPMF是做什么的？

Founded in 1994 and headquartered in Shanghai, Shanghai Pharmaceuticals Holding Co., Ltd. has evolved into a comprehensive pharmaceutical enterprise. As an investment holding company and a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., it is deeply rooted in the Chinese healthcare landscape. The company operates through four key segments: Production, Distribution, Retail, and Others. Its product offerings encompass a wide array of pharmaceuticals, including chemicals and biochemicals, traditional Chinese medicines, healthcare products, and medical devices. These products target various therapeutic areas such as oncology, cerebrocardiovascular diseases, central nervous system disorders, general infections, immunology, digestive and metabolic ailments, and respiratory conditions. Shanghai Pharmaceuticals provides approximately 700 drug varieties. Beyond manufacturing, the company offers extensive pharmaceutical distribution, warehousing, and logistics services. It also manages a network of approximately 2,000 retail chain pharmacies across 24 provinces, complemented by an online drug business. The company extends its services to consulting, asset management, clinical trials, medical aid, and physician and patient education, further solidifying its presence in the healthcare ecosystem.

SHPMF的投资论点是什么？

Shanghai Pharmaceuticals presents a compelling investment case based on its established market position and diversified operations within China's expanding healthcare sector. With a P/E ratio of 11.36 and a dividend yield of 2.37%, the company offers a blend of value and income. Growth catalysts include the increasing demand for healthcare products and services in China, driven by an aging population and rising income levels. The company's extensive distribution network and retail presence provide a competitive edge. However, the may be worth researching risks associated with regulatory changes in the pharmaceutical industry and the competitive pressures from both domestic and international players. The company's profit margin of 2.0% and gross margin of 10.6% indicate areas for potential improvement in operational efficiency.

SHPMF在哪个行业运营？

Shanghai Pharmaceuticals operates within the rapidly growing Chinese pharmaceutical market. The industry is characterized by increasing demand for healthcare products and services, driven by an aging population, rising income levels, and increasing health awareness. The company faces competition from both domestic players and international pharmaceutical giants. Key trends include the increasing adoption of generic drugs, the growing importance of online pharmacies, and the evolving regulatory landscape. The company's extensive distribution network and retail presence provide a competitive advantage in this dynamic market.

Medical - Distribution

Healthcare

SHPMF有哪些增长机遇？

Expansion of Online Pharmacy Business: Shanghai Pharmaceuticals can capitalize on the growing trend of online pharmacies in China. By expanding its online platform and offering a wider range of products and services, the company can reach a larger customer base and increase its market share. The e-commerce market in China is expected to continue its double-digit growth, providing a significant opportunity for the company. Timeline: Ongoing.
Increased Focus on R&D and Innovative Drugs: Investing in research and development to develop innovative drugs can drive future growth. The company can focus on developing drugs for therapeutic areas with unmet needs, such as oncology and CNS disorders. This will not only enhance its product portfolio but also improve its profitability. The Chinese government is also encouraging innovation in the pharmaceutical industry, providing further support for R&D activities. Timeline: Ongoing.
Expansion into Rural Markets: Expanding its retail pharmacy network into rural areas can provide access to a large untapped market. The healthcare needs in rural areas are often underserved, presenting a significant opportunity for growth. The company can leverage its existing distribution network to efficiently serve these markets. Timeline: Upcoming, within 2-3 years.
Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller players can help expand its product portfolio and market reach. This can also provide access to new technologies and expertise. The pharmaceutical industry is consolidating globally, and Shanghai Pharmaceuticals can benefit from this trend. Timeline: Ongoing.
Development of Value-Added Services: The company can further develop its value-added services, such as consulting, asset management, clinical trials, medical aid, and physician and patient education. These services can generate additional revenue streams and enhance customer loyalty. The demand for these services is increasing as healthcare becomes more complex and patients become more informed. Timeline: Ongoing.

Market capitalization of $8.46 billion, reflecting its significant presence in the Chinese pharmaceutical market.
P/E ratio of 11.36, suggesting a potentially undervalued investment relative to its earnings.
Dividend yield of 2.37%, offering a steady income stream for investors.
Gross margin of 10.6%, indicating the profitability of its core business activities.
Beta of 0.33, suggesting lower volatility compared to the overall market.

SHPMF提供哪些产品和服务？

Researches and develops pharmaceutical products.
Manufactures a wide range of drugs, including chemicals, biochemicals, and traditional Chinese medicines.
Distributes pharmaceutical products to hospitals, distributors, and retail pharmacies.
Operates a network of approximately 2,000 retail chain pharmacies.
Provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions.
Engages in online drug business.
Offers consulting services, asset management operations, and clinical trials.
Provides medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals.

SHPMF如何赚钱？

Manufacturing and selling pharmaceutical products.
Providing pharmaceutical distribution and logistics services.
Operating retail pharmacies and selling drugs directly to consumers.
Offering value-added services such as consulting and clinical trials.

Hospitals and healthcare providers.
Pharmaceutical distributors.
Retail pharmacies.
Individual consumers.

Extensive distribution network and retail presence in China.
Diversified product portfolio spanning various therapeutic areas.
Strong brand recognition and reputation in the Chinese pharmaceutical market.
Established relationships with hospitals and healthcare providers.

什么因素可能推动SHPMF股价上涨？

Ongoing: Expansion of the online pharmacy business to capture a larger market share.
Ongoing: Increased investment in R&D to develop innovative drugs and expand the product portfolio.
Upcoming: Potential strategic partnerships and acquisitions to expand market reach and access new technologies.
Ongoing: Development of value-added services to generate additional revenue streams and enhance customer loyalty.
Ongoing: Government policies supporting the growth of the pharmaceutical industry in China.

SHPMF的主要风险是什么？

Potential: Increasing competition from domestic and international players in the Chinese pharmaceutical market.
Potential: Pricing pressures from generic drugs and government regulations.
Potential: Regulatory changes and compliance requirements that could impact operations and profitability.
Potential: Economic slowdown in China that could reduce demand for pharmaceutical products.
Ongoing: Risks associated with operating in the OTC market, including limited liquidity and disclosure.

SHPMF的核心优势是什么？

Extensive distribution network and retail presence in China.
Diversified product portfolio spanning various therapeutic areas.
Strong brand recognition and reputation.
Established relationships with hospitals and healthcare providers.

SHPMF的劣势是什么？

Relatively low profit margin compared to global peers.
Dependence on the Chinese market.
Exposure to regulatory changes in the pharmaceutical industry.
Limited presence in international markets.

SHPMF有哪些机遇？

Expansion into rural markets in China.
Increased focus on R&D and innovative drugs.
Strategic partnerships and acquisitions.
Development of value-added services.

SHPMF面临哪些威胁？

Increasing competition from domestic and international players.
Pricing pressures from generic drugs.
Regulatory changes and compliance requirements.
Economic slowdown in China.

SHPMF的竞争对手是谁？

B. Braun Melsungen AG — Global healthcare company with a focus on medical technology and pharmaceuticals. — (BDUUF)
Eisai Co Ltd — Japanese pharmaceutical company specializing in neurology and oncology. — (ESAIY)
Eisai Co Ltd — Japanese pharmaceutical company specializing in neurology and oncology. — (ESALF)
Grifols SA — Spanish multinational pharmaceutical and chemical manufacturer. — (GIFOF)
Kyowa Kirin Co Ltd — Japanese pharmaceutical company focused on specialty pharmaceuticals. — (KYKOF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Qiuhua Yang
Headquarters: Shanghai, CN
Employees: 49,402
Founded: 2013

AI Insight

AI analysis pending for SHPMF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Shanghai Pharmaceuticals Holding Co., Ltd do?

Shanghai Pharmaceuticals Holding Co., Ltd. is a comprehensive pharmaceutical company operating across the value chain, from research and development to manufacturing, distribution, and retail. The company produces a wide range of pharmaceutical products, including chemicals, biochemicals, and traditional Chinese medicines, targeting various therapeutic areas. Its extensive distribution network and retail pharmacy chain provide a strong market presence in China, complemented by online drug sales and value-added services like consulting and clinical trials.

What do analysts say about SHPMF stock?

AI analysis is currently pending for SHPMF, so an analyst consensus is not available at this time. Key valuation metrics include a P/E ratio of 11.36 and a dividend yield of 2.37%. Growth considerations center on the company's ability to capitalize on the expanding Chinese healthcare market and its investments in R&D. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.

What are the main risks for SHPMF?

The main risks for Shanghai Pharmaceuticals include increasing competition in the Chinese pharmaceutical market, pricing pressures from generic drugs, and regulatory changes that could impact operations. As an OTC-listed company, SHPMF also faces risks associated with limited liquidity and disclosure. Investors should carefully consider these factors and conduct thorough due diligence before investing.